Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eptinezumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Eptinezumab. Displaying page 1 of 1.
    EudraCT Number: 2020-001649-38 Sponsor Protocol Number: 19379A Start Date*: 2022-06-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-004102-29 Sponsor Protocol Number: 18922A Start Date*: 2023-03-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label, single-dose, pharmacokinetic study to evaluate IV eptinezumab in children and adolescents with migraine, followed by an optional, multiple-dose, open-label extension period
    Medical condition: Migraine in children and adolescents Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001657-42 Sponsor Protocol Number: 19140A Start Date*: 2021-06-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001669-35 Sponsor Protocol Number: 19139A Start Date*: 2021-02-01
    Sponsor Name:H. Lundbeck A/S (Lundbeck)
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dua...
    Medical condition: Preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004497-25 Sponsor Protocol Number: 18898A Start Date*: 2020-10-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in pati...
    Medical condition: Migraine in patients with unsuccessful prior preventive treatments
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed) FI (Completed) BE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) SE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001969-37 Sponsor Protocol Number: 19386A Start Date*: 2021-03-05
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache
    Medical condition: Episodic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) FR (Prematurely Ended) BE (Completed) NL (Prematurely Ended) FI (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001009-22 Sponsor Protocol Number: 19356A Start Date*: 2022-06-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003049-40 Sponsor Protocol Number: 20007A Start Date*: 2022-07-22
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in pati...
    Medical condition: Migraine and medication overuse headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10072720 Medication overuse headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001968-28 Sponsor Protocol Number: 19385A Start Date*: 2022-02-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache
    Medical condition: Chronic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) FI (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001306-41 Sponsor Protocol Number: ALD403-CLIN-011 Start Date*: 2017-04-27
    Sponsor Name:Alder BioPharmaceuticals, Inc.
    Full Title: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) DE (Completed) BE (Completed) SK (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 12:09:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA